Rethinking Kawasaki disease diagnosis:Continuing the search for new biomarkers  

作　　者：Yan Pan Fu-Yong Jiao 

机构地区：[1]Department of Pediatrics,The First Affiliated Hospital of Yangtze University,Jingzhou 434000,Hubei Province,China [2]Shaanxi Kawasaki Disease Diagnosis and Treatment Center,Children's Hospital,Shaanxi Provincial People's Hospital of Xi'an,Jiaotong University,Xi'an 710000,Shaanxi Province,China

出　　处：《World Journal of Clinical Cases》2024年第30期6346-6348,共3页世界临床病例杂志

基　　金：Supported by The Hubei Pediatric Alliance Medical Research Project,No.HPAMRP202117.

摘　　要：Recent findings by Yamashita et al report a Kawasaki disease(KD)case with normal biomarker levels,challenging traditional diagnostic paradigms.This editorial explores the implications of such atypical KD presentations,emphasizing the need for novel biomarkers and revised diagnostic guidelines.The case underscores the limitations of current biomarkers,the importance of clinical judgment,and the necessity for comprehensive research to identify new diagnostic tools.Emerging technologies in proteomics and genomics offer potential avenues for discovering reliable biomarkers.Revisiting clinical guidelines to incorporate flexibility for atypical presentations is crucial.Ensuring timely and accurate KD diagnosis,even without elevated traditional biomarkers,prevents severe complications.Future advancements should focus on novel biomarkers to improve patient outcomes.

关 键 词：Kawasaki disease Diagnostic criteria Guide line BIOMARKER TECHNOLOGIES 

分 类 号：R725.4[医药卫生—儿科]